<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="an important protein needed for coronavirus replication, and its inhibitor" exact="cyclosporine" post="A has the ability to suppress coronavirus on a"/>
 <result pre="of the SARS-CoV-2 virus to enter the host cells. However," exact="cyclosporine" post="A has immunosuppressive effects, so the conditions for its"/>
 <result pre="use as an antiviral drug are limited. As a result," exact="cyclosporine" post="A analogues without immunosuppressive side effects have attracted lots"/>
 <result pre="of coronavirus infection, especially coronavirus disease 2019 (COVID-19), and non-immunosuppressive" exact="cyclosporine" post="analogues. Keywords cyclophilin A cyclosporine A COVID-19 SARS-CoV2 Coronavirus"/>
 <result pre="disease 2019 (COVID-19), and non-immunosuppressive cyclosporine analogues. Keywords cyclophilin A" exact="cyclosporine" post="A COVID-19 SARS-CoV2 Coronavirus (CoV) is the general name"/>
 <result pre="isomerase (PPIase) activity. Cell receptors originally found as immunosuppressive drug" exact="cyclosporine" post="A (CsA) were found [7,8]. At this stage, CsA"/>
 <result pre="protein can enhance NFAT activities with Ca2+. CaN, calcineurin; CsA," exact="cyclosporin A;" post="CyPA, cyclophilin A; Nsp1, non-structure protein 1; IL-2, interleukin-2;"/>
 <result pre="a possible target for CoV, and also noted that non-immunosuppressive" exact="cyclosporine" post="derivatives may have the potential to become a panCoV"/>
 <result pre="block SARS-CoV and MERS-CoV replication. Combination treatment with alisporivir and" exact="ribavirin" post="increases the anti-MERS-CoV activity in vitro[39]. Gastrointestinal disorders: PreclinicalChronic"/>
 <result pre="of MERS and SARS CoVs, and in cell-based infection models," exact="ribavirin" post="further enhances alisporivir's antiviral effect [39]. 3 Conclusions and"/>
 <result pre="action in cell signaling pathwaysCell70319923653681379518 28SchreiberS.L.CrabtreeG.R.The mechanism of action of" exact="cyclosporin A" post="and FK506Immunol Today13419921361421374612 29PeelM.ScribnerA.Cyclophilin inhibitors as antiviral agentsBioorg Med"/>
 <result pre="both cyclophilin A and cyclophilin BJ Gen Virol982201719020027902373 35Ma-LauerY.ZhengY.MaleÅ¡eviÄ‡M.Influences of" exact="cyclosporin A" post="and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid"/>
 <result pre="coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive" exact="cyclosporine" post="A-derivatives including AlisporivirVirus Res1842014445324566223 39De WildeA.H.FalzaranoD.Zevenhoven-DobbeJ.C.Alisporivir inhibits MERS- and"/>
 <result pre="activity against hepatitis C virus alone or in combination with" exact="alpha" post="interferonAntimicrob Agents Chemother50920062976298216940091 41HopkinsS.ScorneauxB.HuangZ.SCY-635, a novel nonimmunosuppressive analog of"/>
 <result pre="alpha interferonAntimicrob Agents Chemother50920062976298216940091 41HopkinsS.ScorneauxB.HuangZ.SCY-635, a novel nonimmunosuppressive analog of" exact="cyclosporine" post="that exhibits potent inhibition of hepatitis C virus RNA"/>
</results>
